5 June 2023
Dechra Pharmaceuticals plc announced that it has reached an agreement on the terms of a recommended cash acquisition by EQT.
Dechra Pharmaceuticals plc shareholders will be entitled to receive 3,875 pence in cash for each Dechra share.
The acquisition values Dechra’s entire issued, and to be issued, ordinary share capital at approximately £4,459 million on a fully diluted basis, and implies an enterprise value of £4,882 million and a multiple of approximately 25.9 times Dechra’s EBITDA for the twelve months ended 31 December 2022 of £188 million.
More, Source: Company’s Regulatory Filing